Transition in the SARS-CoV2 antibody profile after Pfizer/BioNtech vaccine inoculation in persons with and without a history of COVID-19

Objective: We investigated whether there was a difference in the antibody profile after Pfizer/BioNtech vaccination in persons who had already been infected with COVID-19 and those who had not. Method: Blood samples were obtained before, after the first dose and after the second dose of Pfizer/BioNtech vaccine inoculation in 4 subjects with a history of COVID-19 infection and 62 subjects without a history of COVID-19 infection after obtaining their informed consent. The differences in the antibody titers were examined between those with and without a prior history of COVID-19. Result: As compared with those without a prior history of COVID-19, those with a prior history of COVID-19 showed significantly higher antibody titers after the first inoculation, and the antibody titers were significantly higher than even those after the second inoculation of subjects without a prior history of COVID-19.

Mild encephalitis/encephalopathy with reversible splenial lesion after COVID-19 vaccination

Objective: To investigate the clinical features of the two cases presenting neurological syndrome after receiving COVID-19 vaccination, who were diagnosed with mild encephalitis/encephalopathy with a reversible splenial lesion (MERS). Background: Neurological symptoms can occur after COVID-19 mRNA vaccination. However, its etiology hasn't been fully revealed. Design/Methods: A 23-year-old previously healthy man (Patient 1) and a 33-year-old woman with a history of depression (Patient 2) developed neurological symptoms approximately one week after receipt of the first standard dose (0.3 mL, intramuscular injection) of COVID-19 mRNA vaccination (Coronavirus Modified Uridine RNA Vaccine (SARS-CoV-2)) (Day 1) and deteriorated over the next week. Clinical course, laboratory and MRI findings were serially analyzed. Results: Patient 1 presented with headache, low-grade fever and memory disturbance (Day 3). Intravenous acyclovir and meropenem were administered under a possible diagnosis of aseptic meningitis but not effective. Patient 2 presented with visual disturbance, headache, dysarthria, a left forearm tremor, dysesthesia of the mouth and distal limbs, and visual agnosia (Day 10). In both patients, reverse transcription polymerase chain reaction test results for severe acute respiratory syndrome coronavirus 2 were negative. Complete blood cell count, blood-chemistry including electrolytes and antibody titers, and cerebrospinal fluid test findings were unremarkable initially. However, second cerebrospinal fluid test of Patient 1 (Day 8) showed pleocytosis (942 cells/μL, normal ≤ 5 cells/μL) and elevated protein levels (181 mg/dL, normal 10-40 mg/dL). Brain MRI on Day 17 in Patient 1 and Day 15 in Patient 2 after receiving the vaccination showed high signal intensity lesions at the midline of the splenium of the corpus callosum. Based on the typical imaging features, the patients were diagnosed with MERS. Intravenous methylprednisolone therapy (1,000 mg/day for 3 days) improved their symptoms and MRI lesion disappeared. Conclusions: MERS should be considered in patients with neurological manifestation after COVID-19 vaccination, even though symptoms were mild and nonspecific.